<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Biophysics and Nanomedicine, Gottfried Schatz Research Centre for Cell Signalling," exact="Metabolism" post="and Aging, Medical University of Graz, Graz, Austria. ruth.prassl@medunigraz.at"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="task for the whole world to deal with. With the" exact="absence of" post="specific drugs or vaccines against SARS-CoV-2, the situation is"/>
 <result pre="the situation is very difficult to control. Apart from the" exact="absence of" post="specific therapies, the lack of knowledge about potential therapeutic"/>
 <result pre="review describes the novel SARS-CoV-2 structure, surface proteins, asymptomatic and" exact="symptomatic" post="transmission in addition to the genotype and phenotype of"/>
 <result pre="in human circulation which have low pathogenicity and caused mild" exact="respiratory" post="symptoms viz NL63 and 229E which are Î± CoVs;"/>
 <result pre="HKU1 which are Î²-CoVs. In the 21st century, two severe" exact="respiratory" post="tract infection (RTI) viz. severe acute respiratory syndrome (SARS)"/>
 <result pre="are Î²-CoVs. In the 21st century, two severe respiratory tract" exact="infection" post="(RTI) viz. severe acute respiratory syndrome (SARS) caused by"/>
 <result pre="21st century, two severe respiratory tract infection (RTI) viz. severe" exact="acute" post="respiratory syndrome (SARS) caused by SARS-CoV (Î²-CoV) emerged in"/>
 <result pre="century, two severe respiratory tract infection (RTI) viz. severe acute" exact="respiratory" post="syndrome (SARS) caused by SARS-CoV (Î²-CoV) emerged in Guangdong"/>
 <result pre="two severe respiratory tract infection (RTI) viz. severe acute respiratory" exact="syndrome" post="(SARS) caused by SARS-CoV (Î²-CoV) emerged in Guangdong province"/>
 <result pre="in Guangdong province of China in 2002â€&quot;2003, and Middle East" exact="respiratory" post="syndrome (MERS) caused by MERS-CoV (Î²-CoV) emerged in Saudi"/>
 <result pre="Guangdong province of China in 2002â€&quot;2003, and Middle East respiratory" exact="syndrome" post="(MERS) caused by MERS-CoV (Î²-CoV) emerged in Saudi Arabia"/>
 <result pre="and in MERS were dromedary camels. SARS and MERS caused" exact="respiratory" post="distress and lung injury leading to pulmonary failure and"/>
 <result pre="and MERS caused respiratory distress and lung injury leading to" exact="pulmonary" post="failure and fatality [[2], [3], [4], [5], [6]]. 1.1"/>
 <result pre="late December 2019, there were clusters of cases with severe" exact="pneumonia" post="due to unknown causes. Most of the initial cases"/>
 <result pre="a quick surveillance system after the SARS outbreak, the patient's" exact="respiratory" post="samples were sent to reference labs for etiological examinations."/>
 <result pre="reference labs for etiological examinations. Assessment of the patients for" exact="viral pneumonia" post="was done by testing the broncho-alveolar lavage fluid using"/>
 <result pre="labs for etiological examinations. Assessment of the patients for viral" exact="pneumonia" post="was done by testing the broncho-alveolar lavage fluid using"/>
 <result pre="coronavirus (2019-nCoV). Later on, the 11th February, WHO termed the" exact="disease" post="as coronavirus disease 2019 (COVID-19) and CSG (Coronavirus Study"/>
 <result pre="on, the 11th February, WHO termed the disease as coronavirus" exact="disease" post="2019 (COVID-19) and CSG (Coronavirus Study Group) of the"/>
 <result pre="to 6.5 [12]. R0 value (represents an average of new" exact="infections" post="produced by an infectious person in a total population)"/>
 <result pre="value (represents an average of new infections produced by an" exact="infectious" post="person in a total population) gives the warning for"/>
 <result pre="of new infections produced by an infectious person in a" exact="total" post="population) gives the warning for virus transmission with respect"/>
 <result pre="Wuhan and other cities of Hubei province were placed under" exact="complete" post="lockdown. There were cases of COVID-19 in individuals who"/>
 <result pre="a screening mechanism in place in order to detect any" exact="symptomatic" post="travelers who were kept under quarantine and were allowed"/>
 <result pre="for the COVID-19 test. It soon became apparent that the" exact="disease" post="could transmit from an asymptomatic person (before the commencement"/>
 <result pre="acknowledged COVID-19 as a Pandemic. As of April 16th, the" exact="total" post="COID-19 cases are almost 2 million worldwide. It is"/>
 <result pre="was recognized as the source of an unidentified form of" exact="viral pneumonia" post="called COVID-19 that originated in Wuhan, China and was"/>
 <result pre="recognized as the source of an unidentified form of viral" exact="pneumonia" post="called COVID-19 that originated in Wuhan, China and was"/>
 <result pre="HCoV229E, which belong to the genus Î±-coronavirus; and HCV-OC43, HCoVHKU1," exact="Severe" post="Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East"/>
 <result pre="which belong to the genus Î±-coronavirus; and HCV-OC43, HCoVHKU1, Severe" exact="Acute" post="Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory"/>
 <result pre="belong to the genus Î±-coronavirus; and HCV-OC43, HCoVHKU1, Severe Acute" exact="Respiratory" post="Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome"/>
 <result pre="to the genus Î±-coronavirus; and HCV-OC43, HCoVHKU1, Severe Acute Respiratory" exact="Syndrome" post="coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus"/>
 <result pre="Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East" exact="Respiratory" post="Syndrome coronavirus (MERS-CoV) that belong to the genus Î²-coronavirus."/>
 <result pre="Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory" exact="Syndrome" post="coronavirus (MERS-CoV) that belong to the genus Î²-coronavirus. CoVs"/>
 <result pre="by 50%), indicating that it evolved from bats but the" exact="intermediate" post="source is not yet known. The phylogenetic analysis revealed"/>
 <result pre="encodes 16 non-structural proteins comprises of approx. 67% of the" exact="total" post="genome while remaining ORF encodes the structural protein and"/>
 <result pre="since in vitro studies by inoculating SARS-CoV-2 in human airway" exact="epithelial" post="cells have shown a cytopathic effect with the cessation"/>
 <result pre="in all the infected patients. However, the Chinese Centre for" exact="Disease" post="Control reports 81% of cases to have mild indications"/>
 <result pre="those diagnosed with other CoVs infections, the most common being" exact="lymphopenia" post="together with low platelet amount and lower levels of"/>
 <result pre="most common being lymphopenia together with low platelet amount and" exact="lower" post="levels of albumin while the levels of creatine kinase,"/>
 <result pre="with the onset of dyspnoea within 5Â days followed by" exact="Acute" post="Respiratory Distress Syndrome within 30% of the cases within"/>
 <result pre="the onset of dyspnoea within 5Â days followed by Acute" exact="Respiratory" post="Distress Syndrome within 30% of the cases within a"/>
 <result pre="of dyspnoea within 5Â days followed by Acute Respiratory Distress" exact="Syndrome" post="within 30% of the cases within a span of"/>
 <result pre="and glomeruli, a serious complication for MERS appears to be" exact="acute" post="kidney injury, however, it rarely occurs in COVID-19 and"/>
 <result pre="glomeruli, a serious complication for MERS appears to be acute" exact="kidney injury," post="however, it rarely occurs in COVID-19 and SARS [22]."/>
 <result pre="occurs in COVID-19 and SARS [22]. As symptoms commence, the" exact="viral" post="loads in COVID-19 were found to be higher in"/>
 <result pre="to SARS-CoV, which caused an epidemic in early 2003. Both" exact="viral" post="strains belong to the B lineage of Î²-coronaviruses genera."/>
 <result pre="smallest among the other foremost structural proteins, predominantly localizes in" exact="vesicle" post="trafficking organelles such as Golgi and ER/Golgi interface thus"/>
 <result pre="virus, tissue tropism, and virus internalization into the host cell." exact="Structural" post="proteins work in synchrony with each other to bring"/>
 <result pre="(viral genomic material) is then released into host cell cytoplasm." exact="Viral" post="genome is translated to form non-structural proteins, which constitute"/>
 <result pre="sub-genomic mRNAs which encode structural and accessory proteins. The new" exact="viral" post="genomic RNA bound to nucleocapsid protein and other accessory"/>
 <result pre="(viral buds) in endoplasmic reticulum and golgi are transported via" exact="vesicle" post="cargoes to fuse with the plasma membrane and finally"/>
 <result pre="cleavage results in 16 putative nonstructural proteins (nsps) such as" exact="viral" post="proteases (nsp3, cysteine protease, and nsp5), RNA-dependent RNA polymerase"/>
 <result pre="other nsps which are expected to be tangled in the" exact="viral" post="transcription and replication. The distal portion of the viral"/>
 <result pre="the viral transcription and replication. The distal portion of the" exact="viral" post="genome towards 3â€² end consists of 12 nested orfs"/>
 <result pre="contribute to the complex transcription and translational properties to the" exact="viral" post="RNA [[36], [37], [38], [39]]. Besides understanding about the"/>
 <result pre="sequences in the sub-genomic mRNAs, and more insight into the" exact="secondary" post="structures of the genomic RNA would enable in development"/>
 <result pre="2), a transmembrane domain and cytoplasmic domain that aids in" exact="viral" post="envelope fusion with host cell membrane via the endosomal"/>
 <result pre="(serine protease) to induce membrane wrapping and efficient internalization [41,42]." exact="Structural" post="analysis demonstrated that the RBD of SARS-CoV-2 bound with"/>
 <result pre="of viruses [44,45]. So far, SARS-CoV-2 was thought to infect" exact="upper" post="respiratory tissue, surprisingly a recent report shows the ability"/>
 <result pre="viruses [44,45]. So far, SARS-CoV-2 was thought to infect upper" exact="respiratory" post="tissue, surprisingly a recent report shows the ability of"/>
 <result pre="In the spike protein of the present pandemic SARS-CoV-2, changes" exact="acquired" post="such as furin-like cleavage site, structural changes at the"/>
 <result pre="the cleavage site LeuGlnâ†&quot; (Ser, Ala, Gly). It attains a" exact="stable" post="active form as an octamer while it's monomer and"/>
 <result pre="to treat COVID-19. 3.4 SARS-CoV-2 RNA dependent RNA polymerase (RdRp)" exact="Viral" post="replication and transcription of SARS CoV-2 is carried out"/>
 <result pre="such as nsp7 and nsp8 and catalyses the development of" exact="viral" post="genomic RNA. The complex has a central groove where"/>
 <result pre="RNA polymerase unit (nsp12) is the promising target to develop" exact="viral" post="inhibitors and the promising drug remdesivir, which has entered"/>
 <result pre="RdRp. 4 Enzymes and pathways as potential therapeutic targets Upon" exact="infection" post="from any microbes, the proteins exposed on the surface"/>
 <result pre="specific immune response is then elicited to fight back these" exact="infectious" post="agents. However, in certain infections, the immune system might"/>
 <result pre="with synthetic drugs would not only help in combating the" exact="infection" post="but might also enable in the recovery of defence"/>
 <result pre="be addressed by the therapeutics development. Drugs to combat SARS-CoV-2" exact="infection" post="are in search. In particular, proteins of SARS-CoV-2 such"/>
 <result pre="polymerase activity Metal ions are an essential part of some" exact="viral" post="proteins and play a vital part in their pathogenesis"/>
 <result pre="or inactivate the protein. Because metal ions can bind to" exact="viral" post="proteins, different metal ion-conjugates were tested for their inhibitory"/>
 <result pre="is vital for replication and also the transcription of the" exact="viral" post="genome. Bismuth compounds efficiently inhibited the helicase activity [54]."/>
 <result pre="virus replication. 4.2 Clathrin-mediated endocytosis as potential targets? Besides targeting" exact="viral" post="proteins, the cellular mechanisms involved in virus internalization can"/>
 <result pre="main treatment method for severely infected patients. In cases of" exact="respiratory" post="failure refractory to oxygen therapy and artificial ventilation may"/>
 <result pre="ventilation may be required while hemodynamic assistance is important for" exact="septic shock" post="management [56]. However, therapeutic treatment is a must for"/>
 <result pre="redevelop a compound /drug for the use in a different" exact="disease" post="other than that of its original use. It is"/>
 <result pre="possible broad-spectrum antiviral drug [62,63]. CQ is reported to prevent" exact="virus infection" post="by elevating the endosomal pH needed for virus/cell fusion"/>
 <result pre="broad-spectrum antiviral drug [62,63]. CQ is reported to prevent virus" exact="infection" post="by elevating the endosomal pH needed for virus/cell fusion"/>
 <result pre="and efficacy of CQ and hydroxychloroquine for treating COVID-19 linked" exact="pneumonia" post="[66]. Reports have so far shown that chloroquine phosphate"/>
 <result pre="36 patients. It stated a substantial decrease in nasopharyngeal swab" exact="viral" post="positivity, relative to control, 6Â days following inclusion in"/>
 <result pre="and 6 patients obtained simultaneous azithromycin (AZM) treatment to avoid" exact="bacterial" post="superinfection. Patients who received AZM were chosen based on"/>
 <result pre="protease inhibitors like LPV and RTV in patients with COVID-19" exact="infection" post="[66]. Initially, LPV and RTV were suspected to suppress"/>
 <result pre="HIV protease inhibitors modify host pathways to interact with coronavirus" exact="infection" post="indirectly, their potency remains a matter of concern. In"/>
 <result pre="was mentioned in a study by Lim et al. The" exact="viral" post="Î²-coronavirus load was begun to decrease after the first"/>
 <result pre="host of virus-like: filoviridae, parmyxoviridae and the coronaviridae (Middle East" exact="Respiratory" post="Syndrome-Corona Virus [MERS CoV], Severe Acute Respiratory Syndrome-Corona Virus"/>
 <result pre="and the coronaviridae (Middle East Respiratory Syndrome-Corona Virus [MERS CoV]," exact="Severe" post="Acute Respiratory Syndrome-Corona Virus 2 [SARS-CoV-2]) [7,76]. The prodrug"/>
 <result pre="the coronaviridae (Middle East Respiratory Syndrome-Corona Virus [MERS CoV], Severe" exact="Acute" post="Respiratory Syndrome-Corona Virus 2 [SARS-CoV-2]) [7,76]. The prodrug of"/>
 <result pre="coronaviridae (Middle East Respiratory Syndrome-Corona Virus [MERS CoV], Severe Acute" exact="Respiratory" post="Syndrome-Corona Virus 2 [SARS-CoV-2]) [7,76]. The prodrug of RDV"/>
 <result pre="2 [SARS-CoV-2]) [7,76]. The prodrug of RDV (GS-443902) constrains the" exact="viral" post="RNA dependent RNA polymerase at the early stage of"/>
 <result pre="RNA dependent RNA polymerase at the early stage of the" exact="viral" post="infectious cycle. Chain termination and lethal mutagenesis are the"/>
 <result pre="dependent RNA polymerase at the early stage of the viral" exact="infectious" post="cycle. Chain termination and lethal mutagenesis are the other"/>
 <result pre="RDV is an antiviral that is known to reduce the" exact="viral" post="load by decreasing viral replication. The animal studies showed"/>
 <result pre="that is known to reduce the viral load by decreasing" exact="viral" post="replication. The animal studies showed that the RDV efficiently"/>
 <result pre="The animal studies showed that the RDV efficiently decrease the" exact="viral" post="load in the lung tissue of MERS-CoV infected mice"/>
 <result pre="bat CoVs, bat CoVs and circulating contemporary human CoV in" exact="primary" post="human lung cells [79]. They also showed that GS-5734"/>
 <result pre="the replication of MERS-CoV and SARS-CoV and thereby reduces the" exact="viral" post="load in primary human epithelial cell cultures. RDV blocks"/>
 <result pre="MERS-CoV and SARS-CoV and thereby reduces the viral load in" exact="primary" post="human epithelial cell cultures. RDV blocks SARS-CoV infection at"/>
 <result pre="SARS-CoV and thereby reduces the viral load in primary human" exact="epithelial" post="cell cultures. RDV blocks SARS-CoV infection at a micromolecular"/>
 <result pre="load in primary human epithelial cell cultures. RDV blocks SARS-CoV" exact="infection" post="at a micromolecular and at a half cytotoxic concentration"/>
 <result pre="of RDV in hospitalized patients with moderate to mild COVID-19" exact="respiratory" post="disease has been initiated by China-Japan friendship hospital, China."/>
 <result pre="RDV in hospitalized patients with moderate to mild COVID-19 respiratory" exact="disease" post="has been initiated by China-Japan friendship hospital, China. The"/>
 <result pre="to be May 2020 [84]. National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) has initiated a multicenter, double-blind, randomized, adaptive,"/>
 <result pre="be May 2020 [84]. National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) has initiated a multicenter, double-blind, randomized, adaptive, placebo-controlled"/>
 <result pre="Ribavirin (RBV) is an antiviral purine nucleoside analog approved for" exact="chronic hepatitis C" post="virus (HCV). It is a broad-spectrum anti-viral drug having"/>
 <result pre="(RBV) is an antiviral purine nucleoside analog approved for chronic" exact="hepatitis C" post="virus (HCV). It is a broad-spectrum anti-viral drug having"/>
 <result pre="(HCV). It is a broad-spectrum anti-viral drug having activity against" exact="hepatitis" post="B and respiratory syncytial virus (MERS-CoV, SARS-CoV-2) [86]. RBV"/>
 <result pre="a broad-spectrum anti-viral drug having activity against hepatitis B and" exact="respiratory" post="syncytial virus (MERS-CoV, SARS-CoV-2) [86]. RBV is metabolized by"/>
 <result pre="its prodrug mono, di and triphosphate metabolites. The synthesis of" exact="viral" post="mRNA polymerase is inhibited by the direct binding of"/>
 <result pre="reduction in the production of defective virions and decreases the" exact="viral" post="load [87]. RBV also competitively inhibits host inosine monophosphate"/>
 <result pre="The decrease in guanosine triphosphate leads to the depletion of" exact="viral" post="protein synthesis and halts the process of viral genome"/>
 <result pre="depletion of viral protein synthesis and halts the process of" exact="viral" post="genome replication [88]. RBV also has an immunomodulatory effect"/>
 <result pre="mRNA capping which results in induction of mutation in the" exact="viral" post="replication is the main reason for considering RBV as"/>
 <result pre="coronavirus (nCoV) isolate hCoV-EMC/2012 in the cell lines with a" exact="lower" post="concentration of both RBV and interferon-Î±, thus making RBV"/>
 <result pre="days [91]. The main adverse effects of RBV are hypocalcemia," exact="hemolytic anemia" post="and hypomagnesemia [92]. RBV should be avoided in patients"/>
 <result pre="[91]. The main adverse effects of RBV are hypocalcemia, hemolytic" exact="anemia" post="and hypomagnesemia [92]. RBV should be avoided in patients"/>
 <result pre="hypomagnesemia [92]. RBV should be avoided in patients with preexisting" exact="cardiac disease" post="and in patients with poor renal function. RBV is"/>
 <result pre="[92]. RBV should be avoided in patients with preexisting cardiac" exact="disease" post="and in patients with poor renal function. RBV is"/>
 <result pre="to assess the effect of combination therapy in suppressing the" exact="viral" post="load, shorten the hospitalization time, recovery and reduce the"/>
 <result pre="time, recovery and reduce the mortality in patients with COVID-19" exact="infection" post="compared with lopinavir/ ritonavir [94]. 5.1.2.4 Arbidol Arbidol (ARB)"/>
 <result pre="approved in China and Russia for the prophylaxis treatment of" exact="respiratory" post="viral infections and influenza [95]. It is a broad-spectrum"/>
 <result pre="in China and Russia for the prophylaxis treatment of respiratory" exact="viral" post="infections and influenza [95]. It is a broad-spectrum antiviral"/>
 <result pre="China and Russia for the prophylaxis treatment of respiratory viral" exact="infections" post="and influenza [95]. It is a broad-spectrum antiviral drug"/>
 <result pre="viruses like the Lassa virus, zika virus, Ebola virus, flavivirus," exact="herpes" post="simplex and in food â€&quot; mouth disease [96]. Furthermore,"/>
 <result pre="Ebola virus, flavivirus, herpes simplex and in food â€&quot; mouth" exact="disease" post="[96]. Furthermore, it has shown activity in vitro against"/>
 <result pre="vitro against a host of other viruses like hantaan virus," exact="chikungunya" post="virus, hepatitis B and C virus, reovirus and coxsackievirus"/>
 <result pre="a host of other viruses like hantaan virus, chikungunya virus," exact="hepatitis" post="B and C virus, reovirus and coxsackievirus [97]. ARB"/>
 <result pre="(HTA) that acts on one or multiple stages of the" exact="viral" post="life cycle and as a direct-acting antiviral (DAA) which"/>
 <result pre="ARB interferes with intracellular trafficking, clathrin-mediated endocytosis and directly with" exact="viral" post="lipid envelope [98]. The interaction of ARB with viral"/>
 <result pre="with viral lipid envelope [98]. The interaction of ARB with" exact="viral" post="glycoprotein aromatic residues that are involved in fusion and"/>
 <result pre="activity [99]. Because of its ability to interact with both" exact="viral" post="proteins and lipids ARB can interfere with the later"/>
 <result pre="lipids ARB can interfere with the later stages of the" exact="viral" post="life cycle [100]. The antiviral activity of ARB against"/>
 <result pre="study conducted in China reveals that ARB effectively inhibits SARS-CoV-2" exact="infection" post="at low concentration of 10â€&quot;30Â Î¼M in vitro. The"/>
 <result pre="Guidelines for the Prevention, Diagnosis and Treatment of Novel Coronavirus-induced" exact="Pneumonia" post="for the tentative treatment of COVID-19. ARB is rapidly"/>
 <result pre="for not more than 10Â days [104]. A phase-4 for" exact="pneumonia" post="caused by SARS-CoV-2, randomized, multicenter, open study has been"/>
 <result pre="the safety and efficacy of ARB in the treatment of" exact="pneumonia" post="induced by SARS-CoV-2 [105]. Another randomized, open study to"/>
 <result pre="interferon-Î± 2b in the treatment of mild to moderate COVID-19" exact="pneumonia" post="has also been initiated [106]. 5.1.2.5 Favipiravir Favipiravir (FPV),"/>
 <result pre="influenza several years ago. It acts by preventing the influenza" exact="viral" post="RNA-dependent polymerase RNA, thus blocking the replication process by"/>
 <result pre="Hospital and the Clinical Medical Research Centre of the National" exact="Infectious" post="Diseases obtained positive results on 14 February. Preliminary outcomes"/>
 <result pre="and the Clinical Medical Research Centre of the National Infectious" exact="Diseases" post="obtained positive results on 14 February. Preliminary outcomes from"/>
 <result pre="obtained positive results on 14 February. Preliminary outcomes from a" exact="total" post="of 80 patients (along with the experimental group and"/>
 <result pre="effects than the LPV / RTV group. In terms of" exact="disease" post="development and viral clearance FPV demonstrated stronger therapeutic responses"/>
 <result pre="LPV / RTV group. In terms of disease development and" exact="viral" post="clearance FPV demonstrated stronger therapeutic responses to COVID-19 [110]."/>
 <result pre="SARS-CoV-2 infection. Cell research demonstrated that DRV reported to inhibit" exact="viral" post="replication at a concentration of 300Â Î¼M in vitro,"/>
 <result pre="the treatment of influenza A and B; it prevents the" exact="viral" post="neuraminidase and thereby prevents the releasing of viral particles"/>
 <result pre="prevents the viral neuraminidase and thereby prevents the releasing of" exact="viral" post="particles from host cells, thus minimising the spread throughout"/>
 <result pre="particles from host cells, thus minimising the spread throughout the" exact="respiratory" post="tract [115]. Usage of Oseltamivir with or without antibiotics"/>
 <result pre="of cells [118]. These are the body's natural defense against" exact="viral infection" post="and also play an important role in combating tumors"/>
 <result pre="cells [118]. These are the body's natural defense against viral" exact="infection" post="and also play an important role in combating tumors"/>
 <result pre="has approved INFs for the treatment of various conditions like" exact="multiple sclerosis," post="hepatitis B and C viral infection, hairy cell leukemia"/>
 <result pre="INFs for the treatment of various conditions like multiple sclerosis," exact="hepatitis" post="B and C viral infection, hairy cell leukemia and"/>
 <result pre="of various conditions like multiple sclerosis, hepatitis B and C" exact="viral infection," post="hairy cell leukemia and Acquired Immuno Deficiency Syndrome (AIDS)"/>
 <result pre="conditions like multiple sclerosis, hepatitis B and C viral infection," exact="hairy cell leukemia" post="and Acquired Immuno Deficiency Syndrome (AIDS) [119]. INFs are"/>
 <result pre="multiple sclerosis, hepatitis B and C viral infection, hairy cell" exact="leukemia" post="and Acquired Immuno Deficiency Syndrome (AIDS) [119]. INFs are"/>
 <result pre="hepatitis B and C viral infection, hairy cell leukemia and" exact="Acquired" post="Immuno Deficiency Syndrome (AIDS) [119]. INFs are the first"/>
 <result pre="and C viral infection, hairy cell leukemia and Acquired Immuno" exact="Deficiency Syndrome" post="(AIDS) [119]. INFs are the first cytokines released during"/>
 <result pre="C viral infection, hairy cell leukemia and Acquired Immuno Deficiency" exact="Syndrome" post="(AIDS) [119]. INFs are the first cytokines released during"/>
 <result pre="(AIDS) [119]. INFs are the first cytokines released during a" exact="viral infection." post="The interferon stimulating genes (ISG) which are mainly involved"/>
 <result pre="decreasing the secretion or metabolism of cytokines by interfering with" exact="viral" post="replication. ISGs further prevents membrane fusion by decreasing the"/>
 <result pre="that higher serum concentration of INF is required to halt" exact="viral" post="replication. Whereas the in vitro studies of INF given"/>
 <result pre="SARS [122]. The combination of INF and ribavirin at a" exact="lower" post="dose showed an inhibitory action on the replication of"/>
 <result pre="of SARS-CoV [123] and MERS-CoV [124]. With respect to coronavirus" exact="infection" post="INFÎ²1 plays an important role because of its protective"/>
 <result pre="of COVID-19. INF is an investigational drug and hence its" exact="complete" post="pharmacokinetic profile is not yet established. However, the half-life"/>
 <result pre="and efficacy of recombinant INFÎ±1b as monotherapy in treating corona" exact="virus infection" post="[126]. In another case, an randomized open-label controlled trial"/>
 <result pre="efficacy of recombinant INFÎ±1b as monotherapy in treating corona virus" exact="infection" post="[126]. In another case, an randomized open-label controlled trial"/>
 <result pre="monotherapy of lopinavir/ ritonavir as a treatment for novel coronavirus" exact="infection" post="has been planned [94]. Peginterferon alfa-2a marketed as Pegasys"/>
 <result pre="marketed as Pegasys has been used in the treartment of" exact="chronic" post="Hepatitis C in combination with Ribavirin. With repect to"/>
 <result pre="as Pegasys has been used in the treartment of chronic" exact="Hepatitis" post="C in combination with Ribavirin. With repect to COVID-19"/>
 <result pre="(NCT04343976) and Pegylated INF Lamda-1A (NCT04388709) in patients with COVID-19" exact="infection" post="have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1 Azithromycin Azithromycin"/>
 <result pre="FDA for the treatment of genitourinary tract infections, enteric and" exact="respiratory" post="tract related infections [129]. Along with its anti-bacterial activity,"/>
 <result pre="treatment of genitourinary tract infections, enteric and respiratory tract related" exact="infections" post="[129]. Along with its anti-bacterial activity, AZ has also"/>
 <result pre="production of interferon-stimulated genes in a rhino virus infected bronchial" exact="epithelial" post="cells [130]. Studies showed that AZ is also effective"/>
 <result pre="the virus by a host of multiple mechanism. AZ inhibits" exact="viral" post="genetic shedding from lysosome and blocks endocytosis by getting"/>
 <result pre="increase in pH levels and thereby limits the replication of" exact="viral" post="genetic material [131]. The anti-viral activity of AZ is"/>
 <result pre="secretion and enables lung function by directly acting on bronchial" exact="epithelial" post="cells [130]. AZ has shown a potential action against"/>
 <result pre="host angiotensin converting enzyme-2 (ACE-2) protein and thereby inhibits the" exact="viral" post="entry into the host cell [133]. The bioavailability of"/>
 <result pre="L/kg. The side effects of AZ include macrolide antibiotic resistances," exact="hearing loss" post="and cardiac arrythmias (QT prolongation) [129]. There are several"/>
 <result pre="combination of chloroquine and AZ is effective in reducing the" exact="viral" post="load in the treatment of COVID-19. Usually a dose"/>
 <result pre="hydroxychloroquine and AZ to prevent the hospitalization or death in" exact="symptomatic" post="adult outpatients with COVID-19 [136]. Gautret et al., conducted"/>
 <result pre="and AZ to prevent the hospitalization or death in symptomatic" exact="adult" post="outpatients with COVID-19 [136]. Gautret et al., conducted a"/>
 <result pre="COVID-19 [136]. Gautret et al., conducted a non-randomized, observational, open-label," exact="external" post="control trial on COVID-19 patients of &amp;gt;12Â yrs age"/>
 <result pre="AZ (250Â mg/ day for 5Â days) successfully reduced the" exact="viral" post="load. The activity of hydroxychloroquine in reducing the viral"/>
 <result pre="the viral load. The activity of hydroxychloroquine in reducing the" exact="viral" post="load was further reinforced by AZ. 5.1.3.2 Tetracycline Tetracyclines"/>
 <result pre="of polyketide antibiotics having a broad-spectrum bacteriostatic activity against various" exact="bacterial infections." post="The bactericidal activity of tetracycline is mainly due to"/>
 <result pre="mainly due to its ability to reversibly bind to the" exact="bacterial" post="ribosomes and there by leading to the leakage of"/>
 <result pre="leading to the leakage of the intracellular components from the" exact="bacterial" post="cell by altering the cytoplasmic membrane [138]. Several studies"/>
 <result pre="and histamine along with cytokines by inducing proliferation of the" exact="respiratory" post="submucosa mast cells. The third possible mechanism of tetracycline"/>
 <result pre="tetracycline in treating COVID-19 is by inhibiting the replication of" exact="viral" post="DNA in the lungs which is mainly attributed to"/>
 <result pre="Actinoplanes teichomyceticus [142]. It is currently approved to treat Gram-positive" exact="bacterial infections" post="like Staphylococcal infections [143]. Teicoplanin has also shown its"/>
 <result pre="teichomyceticus [142]. It is currently approved to treat Gram-positive bacterial" exact="infections" post="like Staphylococcal infections [143]. Teicoplanin has also shown its"/>
 <result pre="is currently approved to treat Gram-positive bacterial infections like Staphylococcal" exact="infections" post="[143]. Teicoplanin has also shown its activity against an"/>
 <result pre="activity against an array of viruses like the influenza virus," exact="hepatitis C" post="virus, Ebola, HIV, flavivirus and on corona virus-like SARS-CoV"/>
 <result pre="of the peptidoglycan cell wall [145]. Thus, teicoplanin specifically stops" exact="bacterial" post="growth by inhibiting the biosynthesis of the bacterial cell"/>
 <result pre="specifically stops bacterial growth by inhibiting the biosynthesis of the" exact="bacterial" post="cell wall [146]. Teicoplanin binds to peptidoglycan and inhibits"/>
 <result pre="freezing [145]. Teicoplanin acts against coronavirus, by inhibiting the genome" exact="viral" post="RNA release and thereby preventing the replication of the"/>
 <result pre="because of teicoplanin acting on the early stage of the" exact="viral" post="life cycle by inhibiting the low pH cleavage of"/>
 <result pre="viral life cycle by inhibiting the low pH cleavage of" exact="viral" post="spike protein by cathepsin L in the late endosome"/>
 <result pre="40â€&quot;70Â L. It is eliminated by the renal pathway [149]." exact="Hypersensitivity" post="at the site of injection is the major side"/>
 <result pre="effect associated with teicoplanin. Other than this it may cause" exact="bronchospasm" post="and anaphylactic shock. Teicoplanin can also cause nephrotoxicity and"/>
 <result pre="nephrotoxicity and ototoxicity. Tachycardia, fatigue, headache, tremors, diarrhea, and elevation" exact="of liver" post="enzymes are the other reported side effects [149]. 5.1.4"/>
 <result pre="complex which is said to play an important role in" exact="viral" post="replication. Studies showed that sirolimus successfully inhibited mTOR signalling"/>
 <result pre="outcomes among the patients hospitalized for the treatment of COVD-19" exact="pneumonia" post="[151]. A placebo controlled, two-arm, double blinded, randomized, phase-I"/>
 <result pre="by the FDA for the treatment of moderate to severe" exact="rheumatoid arthritis." post="It is a janus kinase (JAK) inhibitor which acts"/>
 <result pre="cell function and haematopoiesis. Baricitinib also prevents the formation of" exact="viral" post="particles and intracellular passage of viral cells by binding"/>
 <result pre="prevents the formation of viral particles and intracellular passage of" exact="viral" post="cells by binding to associated protein kinase 1 (AAK1)"/>
 <result pre="test against COVID-19. The patients with COVID-19 are prone to" exact="secondary" post="hemophagocytic lymphohistocytosis (SHL) [153], which leads to an elevated"/>
 <result pre="aid in reducing the inflammation and it also prevents the" exact="viral infection" post="and endocytosis by inducing a inhibitory effect o AAK1"/>
 <result pre="in reducing the inflammation and it also prevents the viral" exact="infection" post="and endocytosis by inducing a inhibitory effect o AAK1"/>
 <result pre="[154]. The main side effects associated with baricitinib are thrombosis," exact="upper" post="respiratory tract infections and malignancy. There are several ongoing"/>
 <result pre="The main side effects associated with baricitinib are thrombosis, upper" exact="respiratory" post="tract infections and malignancy. There are several ongoing clinical"/>
 <result pre="side effects associated with baricitinib are thrombosis, upper respiratory tract" exact="infections" post="and malignancy. There are several ongoing clinical trials for"/>
 <result pre="efficacy of the combination of drugs in treating SARS-CoV-2 associated" exact="pneumonia" post="has been initiated. The aim of this current study"/>
 <result pre="(400Â mg) will be administered to the patients with SARS-CoV-2" exact="pneumonia" post="for 7Â days and the efficacy and safety of"/>
 <result pre="Beaueria nivea. It is widely approved for the treatment of" exact="lupus" post="nephritis vasculitis psoriatic arthritis and as a immunosuppressant agent"/>
 <result pre="nivea. It is widely approved for the treatment of lupus" exact="nephritis" post="vasculitis psoriatic arthritis and as a immunosuppressant agent in"/>
 <result pre="It is widely approved for the treatment of lupus nephritis" exact="vasculitis" post="psoriatic arthritis and as a immunosuppressant agent in organ"/>
 <result pre="is widely approved for the treatment of lupus nephritis vasculitis" exact="psoriatic arthritis" post="and as a immunosuppressant agent in organ transplantation [157]."/>
 <result pre="widely approved for the treatment of lupus nephritis vasculitis psoriatic" exact="arthritis" post="and as a immunosuppressant agent in organ transplantation [157]."/>
 <result pre="bids to the angiotensin converting enzyme-2 (ACE-2) at a low" exact="cytosolic" post="Ph, cyclosporine s known to maintain the cytosolic pH"/>
 <result pre="a low cytosolic Ph, cyclosporine s known to maintain the" exact="cytosolic" post="pH at normal levels and there by aids in"/>
 <result pre="at normal levels and there by aids in decreasing the" exact="viral" post="load [160]. Cytokine storm in SARS-CoV-2 infection is mainly"/>
 <result pre="in decreasing the viral load [160]. Cytokine storm in SARS-CoV-2" exact="infection" post="is mainly caused due to SHL and cyclosporine is"/>
 <result pre="its metabolized in intestine and liver by CYP450 enzymes [158]." exact="Gingival" post="hyperplasia, nephrotoxicity and hyperlipidaemia are the possible side effects"/>
 <result pre="and liver by CYP450 enzymes [158]. Gingival hyperplasia, nephrotoxicity and" exact="hyperlipidaemia" post="are the possible side effects of cyclosporine. Despite of"/>
 <result pre="the first humanized recombinant MAb which is used to treat" exact="autoimmune" post="and inflammatory conditions like cytokine release syndrome, giant cell"/>
 <result pre="autoimmune and inflammatory conditions like cytokine release syndrome, giant cell" exact="arthritis" post="and rheumatoid arthritis. TCZ targets and binds to the"/>
 <result pre="inflammatory conditions like cytokine release syndrome, giant cell arthritis and" exact="rheumatoid arthritis." post="TCZ targets and binds to the membrane bound IL-6"/>
 <result pre="T-cell proliferation by IL-6 [162]. In the course of COVID-19" exact="disease" post="progression, the patients develop conditions like acute interstitial pneumonia,"/>
 <result pre="course of COVID-19 disease progression, the patients develop conditions like" exact="acute" post="interstitial pneumonia, fever, lung injury, arthralgia, leukopenia, thrombocytopenia, myocarditis"/>
 <result pre="like acute interstitial pneumonia, fever, lung injury, arthralgia, leukopenia, thrombocytopenia," exact="myocarditis" post="and biological inflammatory changes which is caused due to"/>
 <result pre="is administered in patients with COVID-19 [163]. Skin reactions, headaches," exact="hypertension" post="and gastrointestinal perforation are the major adverse effects associated"/>
 <result pre="arm clinical trial study has been initiated by the National" exact="Cancer" post="Institute, Naples to evaluate the tolerability and efficacy of"/>
 <result pre="evaluate the tolerability and efficacy of TCZ in treating COVID-19" exact="pneumonia" post="[166]. Another open-label, multi-centre clinical trial has been initiated"/>
 <result pre="the use of TCZ in manging COVID-19 patients with suspected" exact="pulmonary" post="hyperinflammation has been initiated. It is an open-label, randomized"/>
 <result pre="broad-spectrum anti-parasite drug which is approved for the treatment of" exact="onchocerciasis" post="and intestinal strongyloidiasis. Ivermectin acts by selectively binding to"/>
 <result pre="of HIV [168]. It is also known to block the" exact="viral" post="replication of host of viruses including influenza, flavivirus and"/>
 <result pre="anti-viral activity against SARS-CoV-2 virus showed an inhibition of the" exact="viral" post="replication up to 5000-fold within 48Â h which is"/>
 <result pre="mediated by inhibiting the IMP Î±/Î² mediated nuclear import of" exact="viral" post="proteins [170]. A phase-III, double blind, randomized clinical trial"/>
 <result pre="used in treating hypertension. ACE-2 receptors are overexpressed on the" exact="epithelial" post="cells of the oral mucosa and they are also"/>
 <result pre="receptors are overexpressed on the epithelial cells of the oral" exact="mucosa" post="and they are also present immune reactive cells like"/>
 <result pre="and they are also present immune reactive cells like lungs" exact="blood vessels" post="macrophages and intestine [172]. In the case of SARS-CoV"/>
 <result pre="particular, corticosteroids are not approved for treating COVID-19 or any" exact="viral pneumonia" post="[175]. In septic shock, corticosteroids benefit from blunting the"/>
 <result pre="corticosteroids are not approved for treating COVID-19 or any viral" exact="pneumonia" post="[175]. In septic shock, corticosteroids benefit from blunting the"/>
 <result pre="approved for treating COVID-19 or any viral pneumonia [175]. In" exact="septic shock," post="corticosteroids benefit from blunting the host's immune reaction to"/>
 <result pre="from blunting the host's immune reaction to the release of" exact="bacterial" post="toxins. The frequency of shock is remarkably low in"/>
 <result pre="blood flow and thoracic pressure from breathing results in increased" exact="heart" post="activity leading to cardiogenic shock. Corticosteroids can cause damage"/>
 <result pre="pressure from breathing results in increased heart activity leading to" exact="cardiogenic shock." post="Corticosteroids can cause damage via immunosuppressant activity during the"/>
 <result pre="shock. Corticosteroids can cause damage via immunosuppressant activity during the" exact="infection" post="treatment and have failed to offer an advantage in"/>
 <result pre="treatment and have failed to offer an advantage in many" exact="viral" post="epidemics, including influenza infection, respiratory syncytial virus (RSV) infection,"/>
 <result pre="offer an advantage in many viral epidemics, including influenza infection," exact="respiratory" post="syncytial virus (RSV) infection, MERS and SARS [176]. With"/>
 <result pre="on the particular clinical condition (e.g. refractory trauma, artificially ventilated" exact="Acute respiratory distress syndrome" post="(ARDS) patients); however, they are based on data identified"/>
 <result pre="the particular clinical condition (e.g. refractory trauma, artificially ventilated Acute" exact="respiratory" post="distress syndrome (ARDS) patients); however, they are based on"/>
 <result pre="clinical condition (e.g. refractory trauma, artificially ventilated Acute respiratory distress" exact="syndrome" post="(ARDS) patients); however, they are based on data identified"/>
 <result pre="patients infected with COVID-19 (NÂ =Â 201). Eighty-four (41.8%) patients" exact="acquired" post="ARDS and 44 (52.4%) of those died. Methylprednisolone therapy"/>
 <result pre="although immunoglobulin A (IgA) can also be important, especially for" exact="viral" post="mucosal infections. Non-NAbs which bind to the virus but"/>
 <result pre="investigated the effectiveness of CP therapy on 10 severe COVID-19" exact="adult" post="patients, aged 34â€&quot;78Â years. The pilot study findings indicate"/>
 <result pre="levels of anti-SARS-CoV-2 antibodies. Clinical symptoms, such as cough, fever," exact="chest" post="pain and shortness of breath, substantially improved three days"/>
 <result pre="COVID-19 cases. Hitherto, the patients suffering from COVID-19, are receiving" exact="symptomatic" post="treatment due to the unavailability of a specific therapy."/>
 <result pre="mutagenesis. Both ritonavir and lopinavir being protease inhibitors block the" exact="viral" post="cellular entry where ritonavir inhibits Cyt-P450 and prolongs the"/>
 <result pre="inhibits Cyt-P450 and prolongs the half-life of lopinavir. Interferon-beta inhibits" exact="viral" post="replication [192]. In quest of an effective therapeutic moiety,"/>
 <result pre="to have shown good progress using this strategy. Within weeks," exact="viral" post="genome sequences were understood and published which helped in"/>
 <result pre="they are still preferred because of their capability of preventing" exact="lung fibrosis" post="and stopping cytokine storm [194]. Testing of the proposed"/>
 <result pre="2, 2, 2 Oral route Antimalarial, to prevent severe COVID-19" exact="disease" post="Dr. Michael Hill, University of Calgary, Canada, Germany, United"/>
 <result pre="NCT04292730 4 Azithromycin 3 Oral route Antibiotic, to prevent COVD-19" exact="disease" post="progression University of California, San Francisco NCT04332107 5 Atovaquone/Azithromycin"/>
 <result pre="Arbidol 4 Oral route Antiviral, to treat patients with COVID-19" exact="pneumonia" post="Jieming QU, Ruijin Hospital, China NCT04260594 16 Isotretinoin 3"/>
 <result pre="2 oral route, 3 spray To treat patients with COVID-19" exact="pneumonia" post="Second Affiliated Hospital of Wenzhou Medical University, China NCT04273763"/>
 <result pre="1 &amp;amp; 2 Intravenous infusion Iron chelator, to reduce the" exact="Severity of" post="COVID-19 Manifestations Kermanshah University of Medical Sciences, Iran NCT04333550"/>
 <result pre="28 Losartan 1 Oral route Angiotensin receptor blocker, to treat" exact="respiratory" post="failure due to COVID-19 University of Kansas Medical Center,"/>
 <result pre="the maximum tolerated dose for the treatment of COVID-19 Masonic" exact="Cancer" post="Center, University of Minnesota NCT04363346 35 Allogeneic Mesenchymal Stromal"/>
 <result pre="COVID-19 Masonic Cancer Center, University of Minnesota NCT04363346 35 Allogeneic" exact="Mesenchymal" post="Stromal Cells 2 I.V injection To evaluate safety and"/>
 <result pre="evaluate safety and efficacy of cells in patients with COVID-19" exact="Pneumonia" post="Cell Therapy Network, Spain NCT04361942 36 Human Mesenchymal Stem"/>
 <result pre="with COVID-19 Pneumonia Cell Therapy Network, Spain NCT04361942 36 Human" exact="Mesenchymal" post="Stem Cells 1 &amp;amp; 2 I.V Improve immune factor"/>
 <result pre="I.V Improve immune factor and to treat patients with COVID-19" exact="pneumonia" post="Puren Hospital, China NCT04339660 37 Anti-SARS-CoV-2 convalescent plasma 2"/>
 <result pre="Anti-SARS-CoV-2 convalescent plasma 3 I.V infusion To evaluate the efficacy" exact="Central" post="Directorate of the Army Health Service, France,National Institute of"/>
 <result pre="Tocilizumab 2 I.V injection Immunosuppressive, to treat patients with COVID-19" exact="pneumonia" post="National Cancer Institute, Naples, University Hospital Inselspital, Berne, Switzerland"/>
 <result pre="I.V injection Immunosuppressive, to treat patients with COVID-19 pneumonia National" exact="Cancer" post="Institute, Naples, University Hospital Inselspital, Berne, Switzerland NCT04317092, NCT04335071"/>
 <result pre="the safety and efficacy in COVID-19 patients with cytokine release" exact="syndrome" post="Novartis Pharmaceuticals, United States NCT04362813 46 Ruxolitinib 2 â€&quot;"/>
 <result pre="the possibility of potential transmission of diseases. Furthermore, the currently" exact="limited" post="knowledge for therapeutic drugs must be used thoroughly to"/>
 <result pre="Several preclinical trials show that S protein is a key" exact="viral" post="antigen for vaccine development. Detailed clinical trials for already"/>
 <result pre="combinations specially antivirals have proved to be effective against the" exact="disease" post="although the dose and combination of repurposed drugs has"/>
 <result pre="Virology2016John Wiley &amp;amp; Sons 2Chan-YeungM.XuR.-H.SARS: epidemiologyRespirology8 Suppl2003S91410.1046/j.1440-1843.2003.00518.x15018127 3W.H. OrganizationMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)http://www.who.int/emergencies/mers-cov/en2016EriÅŸim Tarihi. 1 (n.d.) 4WangN.ShiX.JiangL.ZhangS.WangD.TongP.GuoD.FuL.CuiY.LiuX.ArledgeK.C.ChenY.-H.ZhangL.WangX.Structure of MERS-CoV"/>
 <result pre="Wiley &amp;amp; Sons 2Chan-YeungM.XuR.-H.SARS: epidemiologyRespirology8 Suppl2003S91410.1046/j.1440-1843.2003.00518.x15018127 3W.H. OrganizationMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)http://www.who.int/emergencies/mers-cov/en2016EriÅŸim Tarihi. 1 (n.d.) 4WangN.ShiX.JiangL.ZhangS.WangD.TongP.GuoD.FuL.CuiY.LiuX.ArledgeK.C.ChenY.-H.ZhangL.WangX.Structure of MERS-CoV spike"/>
 <result pre="coronaviruses as causes of pneumoniaRespirology23201813013710.1111/resp.1319629052924 6ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.LiuX.XuJ.LiD.YuenK.PeirisJ.GuanY.Epidemiology and cause of severe" exact="acute" post="respiratory syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China,"/>
 <result pre="as causes of pneumoniaRespirology23201813013710.1111/resp.1319629052924 6ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.LiuX.XuJ.LiD.YuenK.PeirisJ.GuanY.Epidemiology and cause of severe acute" exact="respiratory" post="syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China, in"/>
 <result pre="causes of pneumoniaRespirology23201813013710.1111/resp.1319629052924 6ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.LiuX.XuJ.LiD.YuenK.PeirisJ.GuanY.Epidemiology and cause of severe acute respiratory" exact="syndrome" post="(SARS) in Guangdong, Peopleâ€™s Republic of China, in February,"/>
 <result pre="patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 8ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.ChenH.-D.ChenJ.LuoY.GuoH.JiangR.-D.LiuM.-Q.ChenY.ShenX.-R.WangX.ZhengX.-S.ZhaoK.ChenQ.-J.DengF.LiuL.-L.YanB.ZhanF.-X.WangY.-Y.XiaoG.-F.ShiZ.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="originNature579202027027310.1038/s41586-020-2012-732015507 9CuiJ.LiF.ShiZ.-L.Origin and evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119210.1038/s41579-018-0118-930531947 10LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="9CuiJ.LiF.ShiZ.-L.Origin and evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119210.1038/s41579-018-0118-930531947 10LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="and evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119210.1038/s41579-018-0118-930531947 10LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="the challengesInt. J. Antimicrob. Agents55202010592410.1016/j.ijantimicag.2020.105924 11W.H. OrganizationLaboratory Testing for Coronavirus" exact="Disease" post="2019 (COVID-19) in Suspected Human Cases: Interim Guidance, 2"/>
 <result pre="of SARS coronavirusJ. Virol.94202010.1128/JVI.00127-20 18ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.NiuP.ZhanF.MaX.WangD.XuW.WuG.GaoG.F.TanW.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.382202072773310.1056/NEJMoa200101731978945 19LiH.LiuS.-M.YuX.-H.TangS.-L.TangC.-K.Coronavirus disease 2019"/>
 <result pre="patients with pneumonia in China, 2019N. Engl. J. Med.382202072773310.1056/NEJMoa200101731978945 19LiH.LiuS.-M.YuX.-H.TangS.-L.TangC.-K.Coronavirus" exact="disease" post="2019 (COVID-19): current status and future perspectivesInt. J. Antimicrob."/>
 <result pre="perspectivesInt. J. Antimicrob. Agents202010595110.1016/j.ijantimicag.2020.105951 20Severe outcomes among patients with coronavirus" exact="disease" post="2019 (COVID-19) â€&quot; United States, February 12â€&quot;March 16, 2020"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 22ChaR.JohJ.-S.JeongI.LeeJ.Y.ShinH.-S.KimG.KimY.C.C.T. of N.M."/>
 <result pre="complications and their prognosis in korean patients with middle east" exact="respiratory" post="syndrome-coronavirus from the central MERS-CoV designated hospitalJ. Korean Med."/>
 <result pre="central MERS-CoV designated hospitalJ. Korean Med. Sci.3020151807181410.3346/jkms.2015.30.12.180726713056 23PeirisJ.ChuC.ChengV.ChanK.HungI.PoonL.LawK.TangB.HonT.ChanC.ChanK.NgJ.ZhengB.NgW.LaiR.GuanY.YuenK.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="community outbreak of coronavirus-associated SARS pneumonia: a prospective studyLancet36120031767177210.1016/S0140-6736(03)13412-512781535 24ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsN. Engl."/>
 <result pre="coronavirus-associated SARS pneumonia: a prospective studyLancet36120031767177210.1016/S0140-6736(03)13412-512781535 24ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 25BÃ¡rcenaM.OostergetelG.T.BartelinkW.FaasF.G.A.VerkleijA.RottierP.J.M.KosterA.J.BoschB.J.Cryo-electron"/>
 <result pre="SARS pneumonia: a prospective studyLancet36120031767177210.1016/S0140-6736(03)13412-512781535 24ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 25BÃ¡rcenaM.OostergetelG.T.BartelinkW.FaasF.G.A.VerkleijA.RottierP.J.M.KosterA.J.BoschB.J.Cryo-electron tomography"/>
 <result pre="of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 25BÃ¡rcenaM.OostergetelG.T.BartelinkW.FaasF.G.A.VerkleijA.RottierP.J.M.KosterA.J.BoschB.J.Cryo-electron tomography of mouse" exact="hepatitis" post="virus: insights into the structure of the coronavirionProc. Natl."/>
 <result pre="novel subgenomic RNAs and noncanonical transcription initiation signals of severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.7920055288529510.1128/JVI.79.9.5288-5295.200515827143 30PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the"/>
 <result pre="subgenomic RNAs and noncanonical transcription initiation signals of severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.7920055288529510.1128/JVI.79.9.5288-5295.200515827143 30PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the MERS"/>
 <result pre="RNAs and noncanonical transcription initiation signals of severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.7920055288529510.1128/JVI.79.9.5288-5295.200515827143 30PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the MERS coronavirus"/>
 <result pre="spike proteinCellular &amp;amp; Molecular Immunology20201310.1038/s41423-020-0374-231611651 33YuF.DuL.OjciusD.M.PanC.JiangS.Measures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
 <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, ChinaMicrobes Infect.222020747910.1016/j.micinf.2020.01.00332017984 34ZhangN.JiangS.DuL.Current advancements and"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerging Microbes &amp;amp; Infections9202022123610.1080/22221751.2020.171990231987001 36SolaI.AlmazÃ¡nF.ZÃºÃ±igaS.EnjuanesL.Continuous and discontinuous"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerging Microbes &amp;amp; Infections9202022123610.1080/22221751.2020.171990231987001 36SolaI.AlmazÃ¡nF.ZÃºÃ±igaS.EnjuanesL.Continuous and discontinuous"/>
 <result pre="38R. Rangan, I.N. Zheludev, R. Das, RNA Genome Conservation and" exact="Secondary" post="Structure in SARS-CoV-2 and SARS-related Viruses, BioRxiv. (2020) 2020.03.27.012906."/>
 <result pre="spike in the prefusion conformationScience36720201260126310.1126/science.abb250732075877 44ChengJ.ZhaoY.XuG.ZhangK.JiaW.SunY.ZhaoJ.XueJ.HuY.ZhangG.The S2 subunit of QX-type" exact="infectious" post="bronchitis coronavirus spike protein is an essential determinant of"/>
 <result pre="in the prefusion conformationScience36720201260126310.1126/science.abb250732075877 44ChengJ.ZhaoY.XuG.ZhangK.JiaW.SunY.ZhaoJ.XueJ.HuY.ZhangG.The S2 subunit of QX-type infectious" exact="bronchitis" post="coronavirus spike protein is an essential determinant of neurotropismViruses11201910.3390/v11100972"/>
 <result pre="membrane fusionCellular &amp;amp; Molecular Immunology20201310.1038/s41423-020-0424-931611651 47XiaS.LiuM.WangC.XuW.LanQ.FengS.QiF.BaoL.DuL.LiuS.QinC.SunF.ShiZ.ZhuY.JiangS.LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="a basis for design of improved Î±-ketoamide inhibitorsScience202010.1126/science.abb3405 50SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe" exact="acute" post="respiratory syndrome coronavirus protein complex integrates processive RNA polymerase"/>
 <result pre="basis for design of improved Î±-ketoamide inhibitorsScience202010.1126/science.abb3405 50SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute" exact="respiratory" post="syndrome coronavirus protein complex integrates processive RNA polymerase and"/>
 <result pre="for design of improved Î±-ketoamide inhibitorsScience202010.1126/science.abb3405 50SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute respiratory" exact="syndrome" post="coronavirus protein complex integrates processive RNA polymerase and exonuclease"/>
 <result pre="as inhibitors of 3CL protease of SARS-CoVFEBS Lett.574200411612010.1016/j.febslet.2004.08.01515358550 52ChaturvediU.C.ShrivastavaR.Interaction of" exact="viral" post="proteins with metal ions: role in maintaining the structure"/>
 <result pre="Infect. Dis.62006676910.1016/S1473-3099(06)70361-916439323 63YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 64VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 64VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent"/>
 <result pre="modelCell Res.23201330030210.1038/cr.2012.16523208422 64VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 65WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends142020727310.5582/bst.2020.0104732074550 68BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.De ClercqE.Design and synthesis of"/>
 <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progression, J. Antimicrob. Chemother.. (n.d.). doi:10.1093/jac/dkaa114. 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.ScolaB.L.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and"/>
 <result pre="of the index patient who caused tertiary transmission of coronavirus" exact="disease" post="2019 in Korea: the application of lopinavir/ritonavir for the"/>
 <result pre="Korea: the application of lopinavir/ritonavir for the treatment of COVID-19" exact="pneumonia" post="monitored by quantitative RT-PCRJ. Korean Med. Sci.35202010.3346/jkms.2020.35.e79 75HoenenT.GrosethA.FeldmannH.Therapeutic strategies"/>
 <result pre="Ebola virus life cycleNat Rev Microbiol17201959360610.1038/s41579-019-0233-231341272 76LoM.K.FeldmannF.GaryJ.M.JordanR.BannisterR.CroninJ.PatelN.R.KlenaJ.D.NicholS.T.CihlarT.ZakiS.R.FeldmannH.SpiropoulouC.F.de WitE.Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challengeSci. Transl. Med.112019eaau924210.1126/scitranslmed.aau924231142680 77BarlowA.LandolfK.M.BarlowB.YeungS.Y.A.HeavnerJ.J.ClaassenC.W.HeavnerM.S.Review"/>
 <result pre="Med.112019eaau924210.1126/scitranslmed.aau924231142680 77BarlowA.LandolfK.M.BarlowB.YeungS.Y.A.HeavnerJ.J.ClaassenC.W.HeavnerM.S.Review of emerging pharmacotherapy for the treatment of coronavirus" exact="disease" post="2019Pharmacotherapy202010.1002/phar.2398 78SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.SpahnJ.E.BauerL.SellersS.PorterD.FengJ.Y.CihlarT.JordanR.DenisonM.R.BaricR.S.Comparative therapeutic efficacy of remdesivir and combination lopinavir,"/>
 <result pre="antiviral activity of remdesivir (GS-5734â&quot;¢) in participants with severe coronavirus" exact="disease" post="(COVID-19) - full text view - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04292899"/>
 <result pre="(n.d.). Https://Clinicaltrials.Gov/Ct2/Show/Nct04280705 (accessed April 9, 2020). 86TanE.L.C.OoiE.E.LinC.-Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845"/>
 <result pre="Dis.10200458158610.3201/eid1004.03045815200845 87TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of" exact="chronic hepatitis" post="CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of action of ribavirin"/>
 <result pre="87TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of chronic" exact="hepatitis" post="CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of action of ribavirin"/>
 <result pre="of interferon-Î±2b and ribavirinSci. Rep.32013168610.1038/srep0168623594967 91DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics142020586010.5582/ddt.2020.0101232147628 92KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common adverse events associated"/>
 <result pre="adverse events associated with the use of ribavirin for severe" exact="acute" post="respiratory syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782 93ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.PeirisJ.S.M.YuenK.Y.Role of lopinavir/ritonavir"/>
 <result pre="events associated with the use of ribavirin for severe acute" exact="respiratory" post="syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782 93ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.PeirisJ.S.M.YuenK.Y.Role of lopinavir/ritonavir in"/>
 <result pre="associated with the use of ribavirin for severe acute respiratory" exact="syndrome" post="in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782 93ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.PeirisJ.S.M.YuenK.Y.Role of lopinavir/ritonavir in the"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Military Medical Research72020410.1186/s40779-020-0233-632029004 105Clinical study of arbidol hydrochloride"/>
 <result pre="105Clinical study of arbidol hydrochloride tablets in the treatment of" exact="pneumonia" post="caused by novel coronavirus - full text view -"/>
 <result pre="treatment/standard treatment in patients with suspected and mild novel coronavirus" exact="pneumonia" post="(COVID-19) - full text view - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04273763"/>
 <result pre="116WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.ZhaoY.LiY.WangX.PengZ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.1585 117KongsaengdaoD.S.A 6 week prospective, open label,"/>
 <result pre="Hydroxychloroquine in Moderate to Critically Ill COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043032992020 118LiuY.-J.IPC: professional" exact="type 1" post="interferon-producing cells and plasmacytoid dendritic cell precursorsAnnu. Rev. Immunol.23200527530610.1146/annurev.immunol.23.021704.11563315771572"/>
 <result pre="Perspect Med.82018a03200310.1101/cshperspect.a03200329311124 120ToturaA.L.BaricR.S.SARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurrent Opinion in Virology2201226427510.1016/j.coviro.2012.04.00422572391 121SchneiderW.M.ChevillotteM.D.RiceC.M.Interferon-stimulated genes: a"/>
 <result pre="Rev. Immunol.32201451354510.1146/annurev-immunol-032713-12023124555472 122OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221"/>
 <result pre="Immunol.32201451354510.1146/annurev-immunol-032713-12023124555472 122OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221 123HensleyL.E.FritzE.A.JahrlingP.B.KarpC.HugginsJ.W.GeisbertT.W.Interferon-Î²"/>
 <result pre="replicationEmerg. Infect. Dis.10200431731910.3201/eid1002.03048215030704 124ChanJ.F.W.ChanK.-H.KaoR.Y.T.ToK.K.W.ZhengB.-J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.-Y.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 125ShenK.-L.YangY.-H.Diagnosis and treatment of 2019 novel"/>
 <result pre="Infect. Dis.10200431731910.3201/eid1002.03048215030704 124ChanJ.F.W.ChanK.-H.KaoR.Y.T.ToK.K.W.ZhengB.-J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.-Y.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 125ShenK.-L.YangY.-H.Diagnosis and treatment of 2019 novel coronavirus"/>
 <result pre="syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 125ShenK.-L.YangY.-H.Diagnosis and treatment of 2019 novel coronavirus" exact="infection" post="in children: a pressing issueWorld J. Pediatr.202010.1007/s12519-020-00344-6s12519-020-00344â€&quot;6 126Efficacy and"/>
 <result pre="antibiotic pathway, pharmacokinetics/pharmacodynamicsPharmacogenet. Genomics27201716416710.1097/FPC.000000000000027028146011 130GielenV.JohnstonS.L.EdwardsM.R.Azithromycin induces anti-viral responses in bronchial" exact="epithelial" post="cellsEur. Respir. J.36201064665410.1183/09031936.0009580920150207 131TytecaD.Azithromycin, a lysosomotropic antibiotic, has distinct"/>
 <result pre="phagocytosis in J774 macrophagesExp. Cell Res.28120028610010.1006/excr.2002.561312441132 132LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.WangM.AliyariS.R.LiX.-F.WuA.MaF.ShiY.Nielsen-SainesK.JungJ.U.QinF.X.-F.QinC.-F.ChengG.Azithromycin protects against zika" exact="virus infection" post="by upregulating virus-induced Type I and III interferon responsesAntimicrob."/>
 <result pre="in J774 macrophagesExp. Cell Res.28120028610010.1006/excr.2002.561312441132 132LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.WangM.AliyariS.R.LiX.-F.WuA.MaF.ShiY.Nielsen-SainesK.JungJ.U.QinF.X.-F.QinC.-F.ChengG.Azithromycin protects against zika virus" exact="infection" post="by upregulating virus-induced Type I and III interferon responsesAntimicrob."/>
 <result pre="Res.28120028610010.1006/excr.2002.561312441132 132LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.WangM.AliyariS.R.LiX.-F.WuA.MaF.ShiY.Nielsen-SainesK.JungJ.U.QinF.X.-F.QinC.-F.ChengG.Azithromycin protects against zika virus infection by upregulating virus-induced" exact="Type I" post="and III interferon responsesAntimicrob. Agents Chemother.63201910.1128/AAC.00394-19e00394-19, /aac/63/12/AAC.00394-19.atom 133DamleB.VourvahisM.WangE.LeaneyJ.CorriganB.Clinical pharmacology"/>
 <result pre="endosome/lysosome and block the entry of ebola virus, middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
 <result pre="and block the entry of ebola virus, middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)J."/>
 <result pre="ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 145ParentiF.Structure and mechanism"/>
 <result pre="virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 145ParentiF.Structure and mechanism of"/>
 <result pre="middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 145ParentiF.Structure and mechanism of action"/>
 <result pre="potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east" exact="respiratory" post="syndrome coronavirus infection as identified by temporal kinome analysisAntimicrob."/>
 <result pre="of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory" exact="syndrome" post="coronavirus infection as identified by temporal kinome analysisAntimicrob. Agents"/>
 <result pre="and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus" exact="infection" post="as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109910.1128/AAC.03659-1425487801 151GuptaN.Sirolimus"/>
 <result pre="analysisAntimicrob. Agents Chemother.5920151088109910.1128/AAC.03659-1425487801 151GuptaN.Sirolimus treatment in hospitalized patients with COVID-19" exact="pneumonia" post="(The SCOPE Trial), clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043416752020 152KraftW.K.RandomizedA.Double-blinded, placebo-controlled trial evaluating the"/>
 <result pre="and pharmacodynamics of sirolimus adjuvant therapy in patients with coronavirus" exact="disease" post="(COVID-19), clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043716402020 153MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: consider cytokine storm syndromes and immunosuppressionLancet39520201033103410.1016/S0140-6736(20)30628-032192578"/>
 <result pre="potentialTherapeutic Advances in Musculoskeletal92017374410.1177/1759720X16687481 155Treatment of moderate to severe coronavirus" exact="disease" post="(COVID-19) in hospitalized patients - full text view -"/>
 <result pre="evaluate efficacy of 3 types of treatment in patients with" exact="pneumonia" post="by COVID-19 - full text view - ClinicalTrials.gov, (n.d.)."/>
 <result pre="162AbdallahH.HsuJ.C.LuP.FettnerS.ZhangX.DouglassW.BaoM.RowellL.BurmesterG.R.KivitzA.Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with" exact="rheumatoid arthritis" post="from 2 randomized, controlled trials: SUMMACTA and BREVACTA: pharmacokinetic"/>
 <result pre="and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid" exact="arthritis" post="from 2 randomized, controlled trials: SUMMACTA and BREVACTA: pharmacokinetic"/>
 <result pre="Care Med.46202084684810.1007/s00134-020-05991-x32125452 165KeizerR.J.HuitemaA.D.R.SchellensJ.H.M.BeijnenJ.H.Clinical pharmacokinetics of therapeutic monoclonal antibodiesClin. Pharmacokinet.49201049350710.2165/11531280-000000000-0000020608753 166National" exact="Cancer" post="Institute, NaplesMulticenter study on the efficacy and tolerability of"/>
 <result pre="the management of patients who have severe COVID-19 with suspected" exact="pulmonary" post="hyperinflammation - full text view - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04377750"/>
 <result pre="safety of hydroxychloroquine and ivermectin in hospitalized no critical patients" exact="secondary" post="to COVID-19 infection: randomized controlled trial, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043911272020 172AnguianoL.RieraM.PascualJ.ValdivielsoJ.M.BarriosC.BetriuA.MojalS.FernÃ¡ndezE.SolerM.J.Circulating angiotensin-converting"/>
 <result pre="trial, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043911272020 172AnguianoL.RieraM.PascualJ.ValdivielsoJ.M.BarriosC.BetriuA.MojalS.FernÃ¡ndezE.SolerM.J.Circulating angiotensin-converting enzyme 2 activity in patients with" exact="chronic" post="kidney disease without previous history of cardiovascular diseaseNephrol. Dial."/>
 <result pre="clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043911272020 172AnguianoL.RieraM.PascualJ.ValdivielsoJ.M.BarriosC.BetriuA.MojalS.FernÃ¡ndezE.SolerM.J.Circulating angiotensin-converting enzyme 2 activity in patients with chronic" exact="kidney disease" post="without previous history of cardiovascular diseaseNephrol. Dial. Transplant.3020151176118510.1093/ndt/gfv02525813276 173LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.ChoeH.FarzanM.Angiotensin-converting"/>
 <result pre="172AnguianoL.RieraM.PascualJ.ValdivielsoJ.M.BarriosC.BetriuA.MojalS.FernÃ¡ndezE.SolerM.J.Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney" exact="disease" post="without previous history of cardiovascular diseaseNephrol. Dial. Transplant.3020151176118510.1093/ndt/gfv02525813276 173LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.ChoeH.FarzanM.Angiotensin-converting"/>
 <result pre="in patients with chronic kidney disease without previous history of" exact="cardiovascular" post="diseaseNephrol. Dial. Transplant.3020151176118510.1093/ndt/gfv02525813276 173LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.ChoeH.FarzanM.Angiotensin-converting enzyme 2 is a functional"/>
 <result pre="antigenicity of the SARS-CoV-2 spike glycoproteinCell1812020281292.e610.1016/j.cell.2020.02.05832155444 175Clinical management of severe" exact="acute" post="respiratory infection when COVID-19 is suspected, (n.d.). https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed"/>
 <result pre="of the SARS-CoV-2 spike glycoproteinCell1812020281292.e610.1016/j.cell.2020.02.05832155444 175Clinical management of severe acute" exact="respiratory" post="infection when COVID-19 is suspected, (n.d.). https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed April"/>
 <result pre="the SARS-CoV-2 spike glycoproteinCell1812020281292.e610.1016/j.cell.2020.02.05832155444 175Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected, (n.d.). https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed April 10,"/>
 <result pre="guidelines on the management of critically ill adults with Coronavirus" exact="Disease" post="2019 (COVID-19)Intensive Care Med.202010.1007/s00134-020-06022-5 178WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with acute"/>
 <result pre="Coronavirus Disease 2019 (COVID-19)Intensive Care Med.202010.1007/s00134-020-06022-5 178WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="Disease 2019 (COVID-19)Intensive Care Med.202010.1007/s00134-020-06022-5 178WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="(COVID-19)Intensive Care Med.202010.1007/s00134-020-06022-5 178WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern. Med.202010.1001/jamainternmed.2020.0994 179ZhouY.-H.QinY.-Y.LuY.-Q.SunF.YangS.HarypursatV.TangS.-Q.HuangY.-Q.HeX.-Q.ZengY.-M.LiY.XuX.-L.ZhaoT.ChenY.-K.Effectiveness of"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern. Med.202010.1001/jamainternmed.2020.0994 179ZhouY.-H.QinY.-Y.LuY.-Q.SunF.YangS.HarypursatV.TangS.-Q.HuangY.-Q.HeX.-Q.ZengY.-M.LiY.XuX.-L.ZhaoT.ChenY.-K.Effectiveness of glucocorticoid therapy"/>
 <result pre="to the current outbreak of COVID-19Infect. Dis. Ther.202010.1007/s40121-020-00295-5 190The Lancet" exact="Infectious" post="DiseasesChallenges of coronavirus disease 2019Lancet Infect. Dis.20202026110.1016/S1473-3099(20)30072-432078810 191KupferschmidtK.CohenJ.WHO launches"/>
 <result pre="of COVID-19Infect. Dis. Ther.202010.1007/s40121-020-00295-5 190The Lancet Infectious DiseasesChallenges of coronavirus" exact="disease" post="2019Lancet Infect. Dis.20202026110.1016/S1473-3099(20)30072-432078810 191KupferschmidtK.CohenJ.WHO launches global megatrial of the"/>
 <result pre="1â€&quot;7. doi:10.1080/21645515.2020.1735227. 199VellingiriB.JayaramayyaK.IyerM.NarayanasamyA.GovindasamyV.GiridharanB.GanesanS.VenugopalA.VenkatesanD.GanesanH.RajagopalanK.RahmanP.K.S.M.ChoS.-G.KumarN.S.SubramaniamM.D.COVID-19: A promising cure for the global panicSci." exact="Total" post="Environ.725202013827710.1016/j.scitotenv.2020.13827732278175 Acknowledgement The authors acknowledge European Molecular Biology Organization"/>
</results>
